

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. (703) 308-0294, on the date shown below.

Dated: April 29, 2003

Signature:

*Nora Durant*  
(Nora Durant)Docket No.: 50913-20001.00  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ira G. Schulman, et al.

Application No.: 09/982,544

Filed: October 17, 2001

Group Art Unit: 1653

Examiner: Kam, Chih-MinFor: METHODS FOR AFFECTING VARIOUS  
DISEASES UTILIZING LXR COMPOUNDSAMENDMENTCommissioner for Patents  
Washington, DC 20231

Dear Sir:

In response to the Office Action dated January 29, 2003 (Paper No. 10), please consider the remarks and amend the above-identified U.S. patent application as follows:

In the Claims

Please cancel claims 14, 18 and 25 without prejudice. Please amend claims 13 and 17 as below:

*B1* 13. (Amended) A method for treating [a metabolic disease] diabetes in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of an LXR[ $\beta$  selective] agonist.

*B2* 17. (Amended). A method of preventing the onset of, reducing the risk of developing, or the risk of recurrence of, diabetes [metabolic disease], said method comprising administering to said mammal a therapeutically-effective amount of an LXR [ $\beta$  selective compound] agonist.

sd-144239